Cresset Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.6M Sell
6,644
-6,989
-51% -$1.53M 0.01% 734
2026
Q1
$2.58M Buy
13,633
+6
+0% +$1.05K 0.01% 499
2025
Q4
$2.32M Buy
13,627
+58
+0.4% +$8.89K 0.01% 527
2025
Q3
$1.79M Buy
13,569
+83
+0.6% +$9.96K 0.01% 570
2025
Q2
$1.43M Sell
13,486
-1,050
-7% -$114K 0.01% 587
2025
Q1
$1.8M Sell
14,536
-2,307
-14% -$301K 0.01% 570
2024
Q4
$2.07M Sell
16,843
-16,606
-50% -$1.96M 0.01% 541
2024
Q3
$3.73M Buy
33,449
+14,905
+80% +$1.63M 0.01% 537
2024
Q2
$1.98M Buy
18,544
+1,893
+11% +$208K 0.01% 727
2024
Q1
$2.01M Buy
16,651
+14,266
+598% +$1.75M 0.01% 639
2023
Q4
$293K Sell
2,385
-1,446
-38% -$180K ﹤0.01% 1500
2023
Q3
$496K Buy
3,831
+1,111
+41% +$148K ﹤0.01% 1185
2023
Q2
$337K Buy
+2,720
New +$366K ﹤0.01% 1473
2019
Q2
– Sell
-485
Closed -$69K – 1071
2019
Q1
$69K Buy
485
+262
+117% +$34.2K ﹤0.01% 674
2018
Q4
$28K Buy
+223
New +$33.1K ﹤0.01% 643

Other funds holding JAZZ

Cresset Asset Management's JAZZ Position: Q2 2026 in Review

Cresset Asset Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 51% in Q2 2026, selling an estimated $1.53M and leaving 6,644 shares worth $1.6M. The position accounts for 0.01% of the portfolio, ranked #734.

Cresset Asset Management first reported a position in JAZZ in Q4 2018 and has held it in 15 quarters since. The position peaked at $3.73M in Q3 2024. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Cresset Asset Management held 6,644 shares of Jazz Pharmaceuticals worth $1.6M as of Q2 2026.
  • Cresset Asset Management sold 6,989 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.53M.
  • Jazz Pharmaceuticals made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #734 holding.
  • Cresset Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and has held it in 15 quarters since.
  • Cresset Asset Management's Jazz Pharmaceuticals position peaked at $3.73M in Q3 2024.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.